Surface Oncology Inc Quick Ratio (SURF) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Surface Oncology Inc   (NASDAQ: SURF)

Surface Oncology Inc 's Quick Ratio

SURF's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2023, Quick Ratio fell to 3.34 a new company low.

Within Biotechnology & Pharmaceuticals industry 103 other companies have achieved higher Quick Ratio than Surface Oncology Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 514 to 1047.

Explain Quick Ratio?
How much Cash & cash equivalents SURF´s has?
What are SURF´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SURF Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change -14.69 % -24.59 % -18.79 % 13.85 % 5.5 %
Y / Y Cash & cash equivalent Change -64.09 % -32.14 % -19.02 % -2.24 % -4.65 %
Quick Ratio MRQ 3.34 6.92 7.68 8.13 7.94
SURF's Total Ranking # 1047 # 514 # 363 # 526 # 498
Seq. Current Liabilities Change 14.09 % -9.29 % -9.63 % -8.79 % 0.84 %
Seq. Cash & cash equivalent Change -44.87 % -18.24 % -14.71 % -6.57 % 4.16 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 104
Healthcare Sector # 527
Overall Market # 1047


Quick Ratio Statistics
High Average Low
11.46 7.71 3.34
(Mar 31 2021)   (Jun 30 2023)




Financial Statements
Surface Oncology Inc 's Current Liabilities $ 17 Millions Visit SURF's Balance sheet
Surface Oncology Inc 's Cash & cash equivalent $ 56 Millions Visit SURF's Balance sheet
Source of SURF's Sales Visit SURF's Sales by Geography


Cumulative Surface Oncology Inc 's Quick Ratio

SURF's Quick Ratio for the trailling 12 Months

SURF Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth -12.36 % -7.23 % 5.9 % 15.25 % 15.88 %
Y / Y Cash & cash equivalent TTM Growth -29.69 % -14.33 % -9.53 % -7.97 % -0.33 %
Quick Ratio TTM 6.52 7.71 7.86 7.86 8.13
Total Ranking TTM # 4023 # 419 # 2587 # 2191 # 3254
Seq. Current Liabilities TTM Growth -4.22 % -6.54 % -4.87 % 2.91 % 1.39 %
Seq. Cash & cash equivalent TTM Growth -18.95 % -8.36 % -4.83 % -0.55 % -1.23 %

Quick ratio ranking by company, industry and sector >> Back to SURF Financial Strength Comparisons >> Go to Compare SURF Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in SURF's Current Liabilities to $16.83 millions, cumulative Quick Ratio to 6.52 below the SURF average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 176 other companies have achieved higher Quick Ratio than Surface Oncology Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 419 to 4023.

Explain Quick Ratio?
How much Cash & cash equivalents SURF´s has?
What are SURF´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 177
Healthcare Sector # 1096
Within the Market # 4023


trailing twelve months Quick Ratio Statistics
High Average Low
9.9 7.65 3.28
(Mar 31 2021)   (Jun 30 2018)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Palisade Bio Inc   9.06 $ 16.403  Millions$ 1.811  Millions
Allogene Therapeutics Inc   8.99 $ 491.962  Millions$ 54.721  Millions
Autolus Therapeutics Plc  8.83 $ 307.500  Millions$ 34.832  Millions
Atyr Pharma Inc   8.78 $ 108.581  Millions$ 12.368  Millions
Leonabio Inc   8.59 $ 186.090  Millions$ 21.662  Millions
Surrozen Inc   8.28 $ 53.395  Millions$ 6.451  Millions
Vir Biotechnology Inc   8.19 $ 1,847.065  Millions$ 225.623  Millions
Century Therapeutics inc   8.16 $ 156.397  Millions$ 19.161  Millions
Kalaris Therapeutics Inc   8.07 $ 246.536  Millions$ 30.563  Millions
Acumen Pharmaceuticals Inc   7.93 $ 67.633  Millions$ 8.531  Millions
Editas Medicine Inc   7.92 $ 431.968  Millions$ 54.513  Millions
Inhibikase Therapeutics Inc   7.66 $ 20.935  Millions$ 2.733  Millions
Passage Bio Inc   7.62 $ 151.480  Millions$ 19.870  Millions
Caribou Biosciences Inc   7.54 $ 259.232  Millions$ 34.375  Millions
In8bio Inc   7.52 $ 16.993  Millions$ 2.259  Millions
Curis Inc   7.50 $ 63.487  Millions$ 8.462  Millions
Apogee Therapeutics Inc   7.10 $ 125.069  Millions$ 17.615  Millions
Prime Medicine Inc   7.01 $ 201.222  Millions$ 28.722  Millions
Ginkgo Bioworks Holdings Inc   6.77 $ 1,105.787  Millions$ 163.331  Millions
Candel Therapeutics Inc   6.76 $ 51.894  Millions$ 7.675  Millions
Tscan Therapeutics Inc   6.76 $ 208.842  Millions$ 30.909  Millions
X4 Pharmaceuticals Inc  6.70 $ 141.309  Millions$ 21.103  Millions
Inhibrx Biosciences Inc   6.58 $ 192.492  Millions$ 29.251  Millions
Immunovant Inc   6.54 $ 329.960  Millions$ 50.438  Millions
Compugen Ltd  6.53 $ 66.534  Millions$ 10.191  Millions
Black Diamond Therapeutics Inc   6.44 $ 89.527  Millions$ 13.898  Millions
Tenaya Therapeutics Inc   6.33 $ 132.505  Millions$ 20.917  Millions
Vivosim Labs Inc   6.08 $ 10.754  Millions$ 1.770  Millions
Senti Biosciences Holdings Inc   5.72 $ 59.635  Millions$ 10.426  Millions
Biontech Se  5.72 $ 13,263.936  Millions$ 2,318.960  Millions

Date modified: 2026-09-08T15:10:59+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.